Ser372
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser372  -  RMP (human)

Site Information
AKRKRKNstGsGHsA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1028301
Available spectra:  1 CST
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 3 , 39 ) , mass spectrometry ( 1 , 2 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 17 , 18 , 19 , 20 , 22 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 ) , mass spectrometry (in vitro) ( 39 ) , mutation of modification site ( 3 , 23 , 39 ) , phospho-antibody ( 3 , 23 ) , western blotting ( 3 , 23 )
Disease tissue studied:
bone cancer ( 3 , 39 ) , breast cancer ( 8 , 18 , 20 ) , breast ductal carcinoma ( 8 ) , HER2 positive breast cancer ( 4 ) , luminal A breast cancer ( 4 ) , luminal B breast cancer ( 4 ) , breast cancer, surrounding tissue ( 4 ) , breast cancer, triple negative ( 4 , 8 ) , gastric cancer ( 19 ) , lung cancer ( 9 , 10 , 11 , 12 , 13 , 14 , 20 , 25 , 28 , 29 ) , non-small cell lung cancer ( 9 , 10 , 12 , 13 , 20 , 28 ) , non-small cell lung adenocarcinoma ( 9 , 10 , 11 , 12 , 13 , 14 , 29 ) , non-small cell large cell lung carcinoma ( 12 ) , non-small cell squamous cell lung carcinoma ( 11 ) , ovarian cancer ( 8 , 23 ) , melanoma skin cancer ( 6 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 26 ) , 293 (epithelial) ( 32 , 33 , 39 ) , A498 (renal) ( 27 ) , A549 (pulmonary) ( 9 ) , breast ( 4 , 8 ) , Cal-12T (pulmonary) ( 13 ) , Calu-3 (pulmonary) ( 10 ) , CL1-0 (pulmonary) ( 25 ) , CL1-1 (pulmonary) ( 25 ) , CL1-2 (pulmonary) ( 25 ) , CL1-5 (pulmonary) ( 25 ) , FU-OV-1 (ovarian) ( 23 ) , H2009 (pulmonary) ( 20 ) , H2077 (pulmonary) ( 20 ) , H2887 (pulmonary) ( 20 ) , H322M (pulmonary) ( 20 ) , HCC15 (pulmonary) ( 11 ) , HCC1937 (breast cell) ( 20 ) , HCC2279 (pulmonary) ( 20 ) , HCC366 (pulmonary) ( 20 ) , HCC44 (pulmonary) ( 13 ) , HCC78 (pulmonary) ( 12 , 20 ) , HCC827 (pulmonary) ( 10 ) , HeLa (cervical) ( 2 , 7 , 17 , 24 , 30 , 31 , 38 , 39 ) , Jurkat (T lymphocyte) ( 15 , 22 , 34 , 40 ) , K562 (erythroid) ( 17 ) , LOU-NH91 (squamous) ( 11 , 20 ) , lung ( 9 , 10 , 11 , 12 , 13 , 14 ) , MCF-7 (breast cell) ( 20 ) , MKN-45 (gastric) ( 19 ) , NCI-H1355 (pulmonary) ( 9 ) , NCI-H1395 (pulmonary) ( 20 ) , NCI-H1437 (pulmonary) ( 13 ) , NCI-H1568 (pulmonary) ( 20 ) , NCI-H157 (pulmonary) ( 20 ) , NCI-H1650 (pulmonary) ( 10 , 28 ) , NCI-H1666 (pulmonary) ( 13 , 20 ) , NCI-H1703 (squamous) ( 11 ) , NCI-H1781 (pulmonary) ( 12 ) , NCI-H1792 (pulmonary) ( 9 ) , NCI-H1975 (pulmonary) ( 10 ) , NCI-H2030 (pulmonary) ( 20 ) , NCI-H2073 (pulmonary) ( 11 ) , NCI-H2106 (pulmonary) ( 10 ) , NCI-H2172 (pulmonary) ( 20 ) , NCI-H2228 (pulmonary) ( 12 ) , NCI-H23 (pulmonary) ( 9 ) , NCI-H2342 (pulmonary) ( 11 ) , NCI-H2405 (pulmonary) ( 13 ) , NCI-H3122 (pulmonary) ( 12 ) , NCI-H3255 (pulmonary) ( 29 , 35 , 36 , 37 ) , NCI-H441 (pulmonary) ( 9 ) , NCI-H460 (pulmonary) ( 20 ) , NCI-H520 (squamous) ( 20 ) , NCI-H647 (pulmonary) ( 20 ) , NCI-H661 (pulmonary) ( 12 ) , ovary ( 8 ) , OVCAR3 (ovarian) ( 23 ) , PC9 (pulmonary) ( 20 ) , SKBr3 (breast cell) ( 18 ) , SKOV-3 (ovarian) ( 23 ) , TOV21G (ovarian) ( 23 ) , U2OS (bone cell) ( 3 , 39 ) , Vero E6-S ('epithelial, kidney') ( 1 ) , WM239A (melanocyte) ( 6 )

Upstream Regulation
Putative in vivo kinases:
p70S6K (human) ( 39 ) , PKACA (human) ( 3 )
Kinases, in vitro:
p70S6K (human) ( 39 ) , PKACA (human) ( 3 )
Treatments:
gefitinib ( 29 ) , glucose_starvation ( 3 ) , IGF-1 ( 39 ) , ischemia ( 8 ) , lapatinib ( 18 ) , metastatic potential ( 25 ) , rapamycin ( 29 , 39 ) , selumetinib ( 6 ) , siRNA ( 39 ) , vemurafenib ( 6 ) , wortmannin ( 29 )

Downstream Regulation
Effects of modification on RMP:
molecular association, regulation ( 3 , 23 , 39 ) , O-GlcNAc glycosylation ( 3 ) , phosphorylation ( 39 )
Effects of modification on biological processes:
apoptosis, induced ( 23 , 39 ) , apoptosis, inhibited ( 3 ) , carcinogenesis, inhibited ( 23 ) , cell growth, inhibited ( 23 , 39 ) , signaling pathway regulation ( 39 )
Inhibit interaction with:
PPP1CC (human) ( 3 , 23 , 39 )

References 

1

Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell
32645325   Curated Info

2

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

3

Burén S, et al. (2016) Regulation of OGT by URI in Response to Glucose Confers c-MYC-Dependent Survival Mechanisms. Cancer Cell 30, 290-307
27505673   Curated Info

4

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

5

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

6

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

7

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

8

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

9

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

10

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

11

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

12

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

13

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

14

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

15

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

16

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

17

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

18

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

19

Rikova K (2012) CST Curation Set: 16145; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966
Curated Info

20

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

21

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

22

Zhou J (2011) CST Curation Set: 12495; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

23

Theurillat JP, et al. (2011) URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell 19, 317-32
21397856   Curated Info

24

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

25

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

26

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

27

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

28

Possemato A (2010) CST Curation Set: 9749; Year: 2010; Biosample/Treatment: cell line, H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

29

Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484   Curated Info

30

Zhou J (2009) CST Curation Set: 6363; Year: 2009; Biosample/Treatment: cell line, HeLa/EGF; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

31

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

32

Guo A (2009) CST Curation Set: 6157; Year: 2009; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

33

Guo A (2009) CST Curation Set: 6156; Year: 2009; Biosample/Treatment: cell line, 293/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

34

Possemato A (2008) CST Curation Set: 5688; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

35

Moritz A (2008) CST Curation Set: 5611; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

36

Moritz A (2008) CST Curation Set: 5614; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

37

Moritz A (2008) CST Curation Set: 5617; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

38

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

39

Djouder N, et al. (2007) S6K1-mediated disassembly of mitochondrial URI/PP1gamma complexes activates a negative feedback program that counters S6K1 survival signaling. Mol Cell 28, 28-40
17936702   Curated Info

40

Moritz A (2006) CST Curation Set: 1975; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611
Curated Info